Abstract
The Epidermal Growth Factor Receptor (EGFR) is a pivotal player in cellular signalling pathways and its dysregulation is implicated in various cancers. Targeting EGFR has emerged as a promising strategy for cancer treatment. This abstract provides Comprehensive analysis of EGFR-targeted therapies, including small molecule tyrosine kinase inhibitors and monoclonal antibodies, reveals their efficacy in suppressing aberrant signalling cascades associated with tumor growth. Mechanisms of resistance, biomarkers for patient stratification, and ongoing clinical trials are discussed to highlight the evolving landscape of EGFR-targeted cancer therapies. The multifaceted nature of EGFR signaling necessitates a personalized approach, emphasizing the need for precision medicine to optimize therapeutic outcomes. This abstract encapsulates the significance and challenges of targeting EGFR for cancer treatment, providing a foundation for further research and clinical advancements in the field. KEYWORDS: Epidermal Growth Factor Receptor (EGFR), Cancer Treatment, Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Biomarkers, Precision Medicine
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: EPRA International Journal of Research & Development (IJRD)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
